Guardant Health's Gains Mask a More Complex Reality The recent surge in Guardant Health's stock price has been touted as a testament to the company's strong financial prospects.
Beneath this surface level optimism, however, lies a more nuanced reality. Guardant Health's decision to hike its 2026 outlook has contributed significantly to investor confidence.
This move is driven in part by growing demand for liquid biopsies, which has been bolstered by increasing cancer diagnoses worldwide.